Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 246

1.

Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study.

van Maurik IS, Vos SJ, Bos I, Bouwman FH, Teunissen CE, Scheltens P, Barkhof F, Frolich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Nobili F, Frisoni GB, Spiru L, Freund-Levi Y, Wallin AK, Hampel H, Soininen H, Tsolaki M, Verhey F, Kłoszewska I, Mecocci P, Vellas B, Lovestone S, Galluzzi S, Herukka SK, Santana I, Baldeiras I, de Mendonça A, Silva D, Chetelat G, Egret S, Palmqvist S, Hansson O, Visser PJ, Berkhof J, van der Flier WM; Alzheimer's Disease Neuroimaging Initiative.

Lancet Neurol. 2019 Sep 13. pii: S1474-4422(19)30283-2. doi: 10.1016/S1474-4422(19)30283-2. [Epub ahead of print]

PMID:
31526625
2.

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.

de Wilde A, Reimand J, Teunissen CE, Zwan M, Windhorst AD, Boellaard R, van der Flier WM, Scheltens P, van Berckel BNM, Bouwman F, Ossenkoppele R.

Alzheimers Res Ther. 2019 Sep 12;11(1):78. doi: 10.1186/s13195-019-0532-x.

3.

Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions.

Weaver NA, Doeven T, Barkhof F, Biesbroek JM, Groeneveld ON, Kuijf HJ, Prins ND, Scheltens P, Teunissen CE, van der Flier WM, Biessels GJ; TRACE-VCI study group.

Neurobiol Aging. 2019 Aug 9. pii: S0197-4580(19)30279-9. doi: 10.1016/j.neurobiolaging.2019.08.001. [Epub ahead of print]

PMID:
31500909
4.

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay.

Shi L, Westwood S, Baird AL, Winchester L, Dobricic V, Kilpert F, Hong S, Franke A, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, Buckley NJ, Kate MT, Scheltens P, Vandenberghe R, Gabel S, Meersmans K, Engelborghs S, De Roeck EE, Sleegers K, Frisoni GB, Blin O, Richardson JC, Bordet R, Molinuevo JL, Rami L, Wallin A, Kettunen P, Tsolaki M, Verhey F, Lleó A, Alcolea D, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Johannsen P, Teunissen CE, Freund-Levi Y, Frölich L, Legido-Quigley C, Barkhof F, Blennow K, Zetterberg H, Baker S, Morgan BP, Streffer J, Visser PJ, Bertram L, Lovestone S, Nevado-Holgado AJ.

Alzheimers Dement. 2019 Sep 5. pii: S1552-5260(19)35118-0. doi: 10.1016/j.jalz.2019.06.4951. [Epub ahead of print]

5.

Three distinct physical behavior types in fatigued patients with multiple sclerosis.

Braakhuis HEM, Berger MAM, van der Stok GA, van Meeteren J, de Groot V, Beckerman H, Bussmann JBJ; TREFAMS-ACE study group.

J Neuroeng Rehabil. 2019 Aug 23;16(1):105. doi: 10.1186/s12984-019-0573-1.

6.

Guidelines for CSF Processing and Biobanking: Impact on the Identification and Development of Optimal CSF Protein Biomarkers.

Hok-A-Hin YS, Willemse EAJ, Teunissen CE, Del Campo M.

Methods Mol Biol. 2019;2044:27-50. doi: 10.1007/978-1-4939-9706-0_2.

PMID:
31432404
7.

Plasma proteome in multiple sclerosis disease progression.

Malekzadeh A, Leurs C, van Wieringen W, Steenwijk MD, Schoonheim MM, Amann M, Naegelin Y, Kuhle J, Killestein J, Teunissen CE.

Ann Clin Transl Neurol. 2019 Jul 31. doi: 10.1002/acn3.771. [Epub ahead of print]

8.

Cerebrospinal Fluid Amyloid-β Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study.

Verwey NA, Teunissen CE, Hoozemans JJM, Rozemuller AJM, Scheltens P, Pijnenburg YAL.

J Alzheimers Dis. 2019;71(1):15-20. doi: 10.3233/JAD-190344.

PMID:
31356209
9.

Pre-analytical stability of novel cerebrospinal fluid biomarkers.

Willemse EAJ, Vermeiren Y, Garcia-Ayllon MS, Bridel C, De Deyn PP, Engelborghs S, van der Flier WM, Jansen EEW, Lopez-Font IB, Mendes V, Manadas B, de Roeck N, Saez-Valero J, Struys EA, Vanmechelen E, Andreasson U, Teunissen CE.

Clin Chim Acta. 2019 Oct;497:204-211. doi: 10.1016/j.cca.2019.07.024. Epub 2019 Jul 23.

PMID:
31348908
10.

Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset.

Altomare D, Ferrari C, Caroli A, Galluzzi S, Prestia A, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen CE, Wall A, Carter SF, Schöll M, Choo ILH, Grimmer T, Redolfi A, Nordberg A, Scheltens P, Drzezga A, Frisoni GB; Alzheimer’s Disease Neuroimaging Initiative.

J Neurol. 2019 Jul 2. doi: 10.1007/s00415-019-09441-7. [Epub ahead of print]

PMID:
31267207
11.

Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease.

Haan JD, van de Kreeke JA, Konijnenberg E, Kate MT, Braber AD, Barkhof F, van Berckel BN, Teunissen CE, Scheltens P, Visser PJ, Verbraak FD, Bouwman FH.

Alzheimers Dement (Amst). 2019 Jun 18;11:463-471. doi: 10.1016/j.dadm.2019.05.002. eCollection 2019 Dec.

12.

Cerebrospinal fluid collection: An informative animation video for patients and caregivers.

Babapour Mofrad R, Visser LNC, Fruijtier AD, Scheltens P, Smets EEMA, van der Flier WM, Teunissen CE.

Alzheimers Dement (Amst). 2019 Jun 12;11:435-438. doi: 10.1016/j.dadm.2019.04.005. eCollection 2019 Dec.

13.

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.

Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE; and the NFL Group, Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ.

JAMA Neurol. 2019 Jun 17. doi: 10.1001/jamaneurol.2019.1534. [Epub ahead of print]

PMID:
31206160
14.

Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?

Haan JD, van de Kreeke JA, van Berckel BN, Barkhof F, Teunissen CE, Scheltens P, Verbraak FD, Bouwman FH.

Alzheimers Dement (Amst). 2019 May 10;11:383-391. doi: 10.1016/j.dadm.2019.03.006. eCollection 2019 Dec.

15.

Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy.

Loonstra FC, Verberk IMW, Wijburg MT, Wattjes MP, Teunissen CE, van Oosten BW, Uitdehaag BMJ, Killestein J, van Kempen ZLE.

Ann Neurol. 2019 Aug;86(2):322-324. doi: 10.1002/ana.25523. Epub 2019 Jun 26. No abstract available.

PMID:
31192473
16.

Systemic and intrathecal immune activation in association with cerebral and cognitive outcomes in paediatric HIV.

Blokhuis C, Peeters CFW, Cohen S, Scherpbier HJ, Kuijpers TW, Reiss P, Kootstra NA, Teunissen CE, Pajkrt D.

Sci Rep. 2019 May 29;9(1):8004. doi: 10.1038/s41598-019-44198-z.

17.

Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project.

Doorduijn AS, Visser M, van de Rest O, Kester MI, de Leeuw FA, Boesveldt S, Fieldhouse JLP, van den Heuvel EGHM, Teunissen CE, Scheltens P, van der Flier WM, de van der Schueren MAE.

Nutrients. 2019 May 23;11(5). pii: E1161. doi: 10.3390/nu11051161.

18.

Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia.

Meeter LHH, Steketee RME, Salkovic D, Vos ME, Grossman M, McMillan CT, Irwin DJ, Boxer AL, Rojas JC, Olney NT, Karydas A, Miller BL, Pijnenburg YAL, Barkhof F, Sánchez-Valle R, Lladó A, Borrego-Ecija S, Diehl-Schmid J, Grimmer T, Goldhardt O, Santillo AF, Hansson O, Vestberg S, Borroni B, Padovani A, Galimberti D, Scarpini E, Rohrer JD, Woollacott IOC, Synofzik M, Wilke C, de Mendonca A, Vandenberghe R, Benussi L, Ghidoni R, Binetti G, Niessen WJ, Papma JM, Seelaar H, Jiskoot LC, de Jong FJ, Donker Kaat L, Del Campo M, Teunissen CE, Bron EE, Van den Berg E, Van Swieten JC.

J Neurol Neurosurg Psychiatry. 2019 Sep;90(9):997-1004. doi: 10.1136/jnnp-2018-319784. Epub 2019 May 23.

19.

Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal.

Vermunt L, van Paasen AJL, Teunissen CE, Scheltens P, Visser PJ, Tijms BM; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2019 Jun 4;92(23):e2699-e2705. doi: 10.1212/WNL.0000000000007609. Epub 2019 May 8.

20.

ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Aβ42, levels in non-demented elderly.

Slot RER, Kester MI, Van Harten AC, Jongbloed W, Bouwman FH, Teunissen CE, Scheltens P, van der Flier WM, Veerhuis R.

Neurobiol Aging. 2019 Jul;79:101-109. doi: 10.1016/j.neurobiolaging.2019.02.017. Epub 2019 Mar 1.

PMID:
31029938
21.

Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project.

van Maurik IS, Slot RER, Verfaillie SCJ, Zwan MD, Bouwman FH, Prins ND, Teunissen CE, Scheltens P, Barkhof F, Wattjes MP, Molinuevo JL, Rami L, Wolfsgruber S, Peters O, Jessen F, Berkhof J, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2019 Apr 16;11(1):33. doi: 10.1186/s13195-019-0487-y.

22.

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.

Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER, Tainta M, Izaguirre A, Reijs BLR, Farotti L, Tsolaki M, Vandenbergue R, Freund-Levi Y, Verhey FRJ, Clarimón J, Fortea J, Frolich L, Santana I, Molinuevo JL, Lehmann S, Visser PJ, Teunissen CE, Zetterberg H, Blennow K.

Alzheimers Dement. 2019 Jun;15(6):742-753. doi: 10.1016/j.jalz.2019.01.015. Epub 2019 Apr 6.

PMID:
30967340
23.

Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study.

Konijnenberg E, den Braber A, Ten Kate M, Tomassen J, Mulder SD, Yaqub M, Teunissen CE, Lammertsma AA, van Berckel BNM, Scheltens P, Boomsma DI, Visser PJ.

Neurobiol Aging. 2019 May;77:58-65. doi: 10.1016/j.neurobiolaging.2019.01.006. Epub 2019 Jan 21.

24.

Serum Neurofilament light correlates with CADASIL disease severity and survival.

Gravesteijn G, Rutten JW, Verberk IMW, Böhringer S, Liem MK, van der Grond J, Aartsma-Rus A, Teunissen CE, Lesnik Oberstein SAJ.

Ann Clin Transl Neurol. 2018 Nov 20;6(1):46-56. doi: 10.1002/acn3.678. eCollection 2019 Jan.

25.

Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples.

Wolfsgruber S, Molinuevo JL, Wagner M, Teunissen CE, Rami L, Coll-Padrós N, Bouwman FH, Slot RER, Wesselman LMP, Peters O, Luther K, Buerger K, Priller J, Laske C, Teipel S, Spottke A, Heneka MT, Düzel E, Drzezga A, Wiltfang J, Sikkes SAM, van der Flier WM, Jessen F; Euro-SCD working group.

Alzheimers Res Ther. 2019 Jan 17;11(1):8. doi: 10.1186/s13195-018-0463-y.

26.

Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis.

Chatterjee M, Koel-Simmelink MJ, Verberk IM, Killestein J, Vrenken H, Enzinger C, Ropele S, Fazekas F, Khalil M, Teunissen CE.

Mult Scler J Exp Transl Clin. 2018 Dec 24;4(4):2055217318819535. doi: 10.1177/2055217318819535. eCollection 2018 Oct-Dec.

27.

Computer-assisted prediction of clinical progression in the earliest stages of AD.

Rhodius-Meester HFM, Liedes H, Koikkalainen J, Wolfsgruber S, Coll-Padros N, Kornhuber J, Peters O, Jessen F, Kleineidam L, Molinuevo JL, Rami L, Teunissen CE, Barkhof F, Sikkes SAM, Wesselman LMP, Slot RER, Verfaillie SCJ, Scheltens P, Tijms BM, Lötjönen J, van der Flier WM.

Alzheimers Dement (Amst). 2018 Oct 8;10:726-736. doi: 10.1016/j.dadm.2018.09.001. eCollection 2018.

28.

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result.

Westwood S, Baird AL, Hye A, Ashton NJ, Nevado-Holgado AJ, Anand SN, Liu B, Newby D, Bazenet C, Kiddle SJ, Ward M, Newton B, Desai K, Tan Hehir C, Zanette M, Galimberti D, Parnetti L, Lleó A, Baker S, Narayan VA, van der Flier WM, Scheltens P, Teunissen CE, Visser PJ, Lovestone S.

Front Aging Neurosci. 2018 Dec 11;10:409. doi: 10.3389/fnagi.2018.00409. eCollection 2018.

29.

The plasma peptides of ovarian cancer.

Dufresne J, Bowden P, Thavarajah T, Florentinus-Mefailoski A, Chen ZZ, Tucholska M, Norzin T, Ho MT, Phan M, Mohamed N, Ravandi A, Stanton E, Slutsky AS, Dos Santos CC, Romaschin A, Marshall JC, Addison C, Malone S, Heyland D, Scheltens P, Killestein J, Teunissen CE, Diamandis EP, Michael Siu KW, Marshall JG.

Clin Proteomics. 2018 Dec 21;15:41. doi: 10.1186/s12014-018-9215-z. eCollection 2018.

30.

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease.

Babapour Mofrad R, Schoonenboom NSM, Tijms BM, Scheltens P, Visser PJ, van der Flier WM, Teunissen CE.

Alzheimers Dement (Amst). 2018 Nov 12;11:1-9. doi: 10.1016/j.dadm.2018.10.004. eCollection 2019 Dec.

31.

Contactins in the central nervous system: role in health and disease.

Chatterjee M, Schild D, Teunissen CE.

Neural Regen Res. 2019 Feb;14(2):206-216. doi: 10.4103/1673-5374.244776. Review.

32.

Differential Expression of Tissue Transglutaminase Splice Variants in Peripheral Blood Mononuclear Cells of Primary Progressive Multiple Sclerosis Patients.

Sestito C, Brevé JJP, Killestein J, Teunissen CE, Wilhelmus MMM, Drukarch B, van Dam AM.

Med Sci (Basel). 2018 Nov 27;6(4). pii: E108. doi: 10.3390/medsci6040108.

33.

The Bri2 and Bri3 BRICHOS Domains Interact Differently with Aβ42 and Alzheimer Amyloid Plaques.

Dolfe L, Tambaro S, Tigro H, Del Campo M, Hoozemans JJM, Wiehager B, Graff C, Winblad B, Ankarcrona M, Kaldmäe M, Teunissen CE, Rönnbäck A, Johansson J, Presto J.

J Alzheimers Dis Rep. 2018 Feb 16;2(1):27-39. doi: 10.3233/ADR-170051.

34.

Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study.

Legdeur N, Badissi M, Carter SF, de Crom S, van de Kreeke A, Vreeswijk R, Trappenburg MC, Oudega ML, Koek HL, van Campen JP, Keijsers CJPW, Amadi C, Hinz R, Gordon MF, Novak G, Podhorna J, Serné E, Verbraak F, Yaqub M, Hillebrand A, Griffa A, Pendleton N, Kramer SE, Teunissen CE, Lammertsma A, Barkhof F, van Berckel BNM, Scheltens P, Muller M, Maier AB, Herholz K, Visser PJ.

BMC Geriatr. 2018 Nov 26;18(1):289. doi: 10.1186/s12877-018-0984-z.

35.

Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy.

Chakraborty A, Kamermans A, van Het Hof B, Castricum K, Aanhane E, van Horssen J, Thijssen VL, Scheltens P, Teunissen CE, Fontijn RD, van der Flier WM, de Vries HE.

Brain. 2018 Dec 1;141(12):3377-3388. doi: 10.1093/brain/awy274.

PMID:
30462206
36.

α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.

van Steenoven I, Majbour NK, Vaikath NN, Berendse HW, van der Flier WM, van de Berg WDJ, Teunissen CE, Lemstra AW, El-Agnaf OMA.

Mov Disord. 2018 Nov;33(11):1724-1733. doi: 10.1002/mds.111. Epub 2018 Nov 15. Erratum in: Mov Disord. 2019 Jan;34(1):159.

37.

No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients.

Bridel C, Eijlers AJC, van Wieringen WN, Koel-Simmelink M, Leurs CE, Schoonheim MM, Killestein J, Teunissen CE.

Front Mol Neurosci. 2018 Oct 31;11:371. doi: 10.3389/fnmol.2018.00371. eCollection 2018.

38.

Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project.

Willemse EAJ, van Maurik IS, Tijms BM, Bouwman FH, Franke A, Hubeek I, Boelaarts L, Claus JJ, Korf ESC, van Marum RJ, Roks G, Schoonenboom N, Verwey N, Zwan MD, Wahl S, van der Flier WM, Teunissen CE.

Alzheimers Dement (Amst). 2018 Sep 12;10:563-572. doi: 10.1016/j.dadm.2018.08.006. eCollection 2018.

39.

Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline.

Ten Kate M, Dicks E, Visser PJ, van der Flier WM, Teunissen CE, Barkhof F, Scheltens P, Tijms BM; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2018 Dec 1;141(12):3443-3456. doi: 10.1093/brain/awy264.

PMID:
30351346
40.

Novel CSF biomarkers to discriminate FTLD and its pathological subtypes.

Del Campo M, Galimberti D, Elias N, Boonkamp L, Pijnenburg YA, van Swieten JC, Watts K, Paciotti S, Beccari T, Hu W, Teunissen CE.

Ann Clin Transl Neurol. 2018 Sep 7;5(10):1163-1175. doi: 10.1002/acn3.629. eCollection 2018 Oct.

41.

Clinical phenotype, atrophy, and small vessel disease in APOEε2 carriers with Alzheimer disease.

Groot C, Sudre CH, Barkhof F, Teunissen CE, van Berckel BNM, Seo SW, Ourselin S, Scheltens P, Cardoso MJ, van der Flier WM, Ossenkoppele R.

Neurology. 2018 Nov 13;91(20):e1851-e1859. doi: 10.1212/WNL.0000000000006503. Epub 2018 Oct 19. Erratum in: Neurology. 2019 Jul 16;93(3):135.

PMID:
30341156
42.

Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease-Data from three memory clinic studies.

Hu X, Teunissen CE, Spottke A, Heneka MT, Düzel E, Peters O, Li S, Priller J, Buerger K, Teipel S, Laske C, Verfaillie SCJ, Barkhof F, Coll-Padrós N, Rami L, Molinuevo JL, van der Flier WM, Jessen F.

Alzheimers Dement. 2019 Feb;15(2):185-193. doi: 10.1016/j.jalz.2018.09.002. Epub 2018 Oct 12.

PMID:
30321506
43.

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.

Scheltens P, Hallikainen M, Grimmer T, Duning T, Gouw AA, Teunissen CE, Wink AM, Maruff P, Harrison J, van Baal CM, Bruins S, Lues I, Prins ND.

Alzheimers Res Ther. 2018 Oct 12;10(1):107. doi: 10.1186/s13195-018-0431-6.

44.

Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals.

Tijms BM, Vermunt L, Zwan MD, van Harten AC, van der Flier WM, Teunissen CE, Scheltens P, Visser PJ; for ADNI.

Ann Clin Transl Neurol. 2018 Jul 20;5(9):1037-1047. doi: 10.1002/acn3.615. eCollection 2018 Sep.

45.

Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes.

Verberk IMW, Slot RE, Verfaillie SCJ, Heijst H, Prins ND, van Berckel BNM, Scheltens P, Teunissen CE, van der Flier WM.

Ann Neurol. 2018 Nov;84(5):648-658. doi: 10.1002/ana.25334. Epub 2018 Oct 4.

46.

Neurofilaments as biomarkers in neurological disorders.

Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle J.

Nat Rev Neurol. 2018 Oct;14(10):577-589. doi: 10.1038/s41582-018-0058-z. Review.

PMID:
30171200
47.

Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change.

Reus LM, Vijverberg EG, Tijms BM, Kate MT, Gossink F, Krudop WA, Campo MD, Teunissen CE, Barkhof F, van der Flier WM, Visser PJ, Dols A, Pijnenburg YA.

J Psychiatr Res. 2018 Sep;104:183-191. doi: 10.1016/j.jpsychires.2018.07.014. Epub 2018 Aug 1.

PMID:
30103065
48.

Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results.

Slot RER, Verfaillie SCJ, Overbeek JM, Timmers T, Wesselman LMP, Teunissen CE, Dols A, Bouwman FH, Prins ND, Barkhof F, Lammertsma AA, Van Berckel BNM, Scheltens P, Sikkes SAM, Van der Flier WM.

Alzheimers Res Ther. 2018 Aug 7;10(1):76. doi: 10.1186/s13195-018-0390-y.

49.

The EMIF-AD PreclinAD study: study design and baseline cohort overview.

Konijnenberg E, Carter SF, Ten Kate M, den Braber A, Tomassen J, Amadi C, Wesselman L, Nguyen HT, van de Kreeke JA, Yaqub M, Demuru M, Mulder SD, Hillebrand A, Bouwman FH, Teunissen CE, Serné EH, Moll AC, Verbraak FD, Hinz R, Pendleton N, Lammertsma AA, van Berckel BNM, Barkhof F, Boomsma DI, Scheltens P, Herholz K, Visser PJ.

Alzheimers Res Ther. 2018 Aug 4;10(1):75. doi: 10.1186/s13195-018-0406-7.

50.

Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease.

Scheltens NME, van der Weijden K, Adriaanse SM, van Assema D, Oomen PP, Krudop WA, Lammertsma AA, Barkhof F, Koene T, Teunissen CE, Scheltens P, van der Flier WM, Pijnenburg YAL, Yaqub M, Ossenkoppele R, van Berckel BNM.

Neuroimage Clin. 2018 May 22;19:625-632. doi: 10.1016/j.nicl.2018.05.024. eCollection 2018.

Supplemental Content

Loading ...
Support Center